Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
PAREXEL International Reports First Quarter Fiscal Year 2017 Results and Announces New Share Repurchase Program
October 26, 2016 4:02 PM EDTFirst Quarter Fiscal Year 2017 Results (compared to First Quarter Fiscal Year 2016)
GAAP diluted earnings per share of $0.75, up 66.7%; adjusted earnings per share of $0.76, up 8.6% Service revenue of $500.9 million, down 2.2%; constant currency revenue decline of 2.4% Gross new business of $930 million Company guides to GAAP EPS of $3.55-$3.89 and adjusted EPS of $3.71-$4.05 for Fiscal Year 2017 Board approved new $200 million share repurchase programBOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) today reported... More
BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
October 25, 2016 8:30 AM EDTReport ranks PRA Health Sciences and INC Research as the most active CROs
NEW YORK--(BUSINESS WIRE)-- BioPharm Insight (BPI), the most comprehensive life science market intelligence and analytics solution, today released its exclusive... More
